Matthew R. Smith, PhD, MD, on Prostate Cancer: Phase III Data on Darolutamide, Androgen Deprivation, and Docetaxel
2022 ASCO Genitourinary Cancers Symposium
Matthew R. Smith, PhD, MD, of Massachusetts General Hospital Cancer Center, discusses overall survival findings from the ARASENS trial, which assessed the efficacy of the androgen receptor inhibitor darolutamide vs placebo in combination with androgen-deprivation therapy and docetaxel for patients with metastatic hormone-sensitive prostate cancer (Abstract 13).
The ASCO Post Staff
Simon J. Crabb, PhD, MBBS, of the Southampton Experimental Cancer Medicine Centre, discusses data from the ATLANTIS trial, in which the authors hypothesized that switch maintenance therapy with the PARP inhibitor rucaparib, in patients who have derived clinical benefit from first-line chemotherapy, may improve outcomes for those with metastatic urothelial carcinoma that harbored a composite biomarker for DNA repair deficiency (Abstract 436).
The ASCO Post Staff
Tanya B. Dorff, MD, of City of Hope National Medical Center, discusses the first-in-human phase I findings showing that prostate stem cell antigen (PSCA) CAR T-cell therapy is feasible in patients with metastatic castration-resistant prostate cancer, with preliminary antitumor activity exhibited.
The ASCO Post Staff
Axel Bex, MD, PhD, of The Netherlands Cancer Institute, discusses an efficacy, safety, and biomarker analysis of neoadjuvant avelumab and axitinib in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (Abstract 289).
The ASCO Post Staff
Xin Gao, MD, of Massachusetts General Hospital, discusses phase I/II findings on bavdegalutamide, an androgen receptor protein degrader, which showed clinical activity in heavily pretreated patients with metastatic castration-resistant prostate cancer who received one to two prior novel hormonal agents.
The ASCO Post Staff
Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, discusses findings from the largest digital survey conducted in patients with prostate cancer, allowing identification of unmet needs in the patient journey. Preliminary data suggest that lower rates of screening may correlate with higher rates of symptoms at diagnosis and potentially later-stage diagnosis.
